| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(96)06255-1 |
| P698 | PubMed publication ID | 9111538 |
| P50 | author | Joshua Shemer | Q6982518 |
| Manfred S. Green | Q60299906 | ||
| Shai Ashkenazi | Q68707920 | ||
| P2093 | author name string | M Gdalevich | |
| D Cohen | |||
| J B Robbins | |||
| R Schneerson | |||
| T L Hale | |||
| C Block | |||
| D N Taylor | |||
| I Ashkenazi | |||
| M Yavzori | |||
| M S Green | |||
| R Slepon | |||
| J C Sadoff | |||
| G Robin | |||
| D Pavliakova | |||
| N Orr | |||
| P2860 | cites work | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid | Q33607442 |
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers | Q35523144 | ||
| Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis | Q40211202 | ||
| Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects | Q40784590 | ||
| Reduction of transmission of shigellosis by control of houseflies (Musca domestica) | Q43310938 | ||
| Interruption of shigellosis by hand washing | Q43324822 | ||
| Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis | Q44965347 | ||
| Inoculum size in shigellosis and implications for expected mode of transmission | Q47172816 | ||
| Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. | Q50464343 | ||
| Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. | Q54624735 | ||
| Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine. | Q54739573 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine | Q70637440 | ||
| Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzas type b conjugate vaccines | Q71853766 | ||
| The response of man to virulent Shigella flexneri 2a | Q72377709 | ||
| Recent trends in the epidemiology of Shigella species in Israel | Q72720471 | ||
| P433 | issue | 9046 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| Shigella sonnei | Q6382438 | ||
| P304 | page(s) | 155-159 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. | |
| P478 | volume | 349 |
| Q49210830 | A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country |
| Q33577932 | A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni |
| Q28767862 | A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology |
| Q33678906 | A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1 |
| Q33975799 | Active immunization in the United States: developments over the past decade |
| Q64948328 | Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. |
| Q52875091 | An Approach to Identify and Characterize a Subunit Candidate Shigella Vaccine Antigen. |
| Q46174437 | An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model |
| Q37668395 | An update on vaccines against Shigella |
| Q39519924 | Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection |
| Q64114469 | Booster Vaccination With GVGH 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial |
| Q37426039 | Carbohydrate vaccines: developing sweet solutions to sticky situations? |
| Q37113756 | Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010 |
| Q92801042 | Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate |
| Q45756775 | Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1. |
| Q34394744 | Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q34003957 | Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice |
| Q35623292 | Conjugate vaccines. |
| Q38683902 | Correlates of protection for enteric vaccines |
| Q73549078 | DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin |
| Q46938617 | Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine |
| Q36444089 | Enteric infections and the vaccines to counter them: future directions |
| Q30443288 | Enteric infections, diarrhea, and their impact on function and development |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q91166657 | Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection |
| Q92261979 | How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella? |
| Q40192692 | Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward |
| Q38952300 | Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae. |
| Q33987735 | Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates. |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q37640115 | Inactivated and subunit vaccines to prevent shigellosis |
| Q34008961 | Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium |
| Q39517102 | Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine |
| Q37309260 | Lipopolysaccharide: a tool and target in enterobacterial vaccine development |
| Q36689023 | Live-attenuated Shigella vaccines |
| Q77148368 | Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of th |
| Q52018706 | Modulation of the serological response to meningococcal polysaccharides by cytokines. |
| Q35844488 | O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative |
| Q33835015 | Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine |
| Q52336351 | Over-expression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx/Wzy-dependent pathway enhances production of defined modal length O polysaccharide polymers for use as haptens in glycoconjugate vaccines. |
| Q34003647 | Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam |
| Q46799503 | Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. |
| Q34120926 | Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults |
| Q33213069 | Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia |
| Q53701548 | Potential targets for next generation anti-microbial glycoconjugate vaccines. |
| Q51696552 | Preclinical studies on new proteins as carrier for glycoconjugate vaccines. |
| Q34008763 | Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity |
| Q44891342 | Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease |
| Q34974972 | Prevention and self-treatment of traveler's diarrhea |
| Q35924773 | Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q89140388 | Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends |
| Q28343287 | Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 |
| Q78171100 | Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines |
| Q39397885 | Reaching a consensus on management practices and vaccine development targets for mitigation of infectious diarrhoea among deployed US military forces |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q36842967 | Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates. |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q59809065 | Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: Results of a Phase 2, randomized, double-blind placebo-controlled trial |
| Q34008338 | Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults |
| Q102056730 | Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study |
| Q40501431 | Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q33767325 | Salmonella and Shigella species. |
| Q43828620 | Serological cross-reaction between O-antigens of Shigella dysenteriae type 4 and an environmental Escherichia albertii isolate. |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q62010509 | Serum antibodies to Vibrio vulnificus biotype 3 lipopolysaccharide and susceptibility to disease caused by the homologous V. vulnificus biotype |
| Q33999534 | Serum immunoglobulin G antibody responses to Bordetella pertussis lipooligosaccharide and B. parapertussis lipopolysaccharide in children with pertussis and parapertussis |
| Q35946462 | Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q33876179 | Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America |
| Q34003433 | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q56383780 | Shigellosis |
| Q41452318 | Shigellosis: from molecular pathogenesis of infection to protective immunity and vaccine development |
| Q34002606 | Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. |
| Q33768943 | Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis |
| Q33753424 | Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis |
| Q45237263 | Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection |
| Q37194696 | Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates |
| Q47971087 | Systemic immunization with urease protects mice against Helicobacter pylori infection |
| Q26825840 | The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary Dysentery |
| Q36993963 | The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain |
| Q34424977 | The structure of the Escherichia coli O148 lipopolysaccharide core region and its linkage to the O-specific polysaccharide. |
| Q39511268 | Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a |
| Q37628007 | Toward a new vaccine for pertussis |
| Q34002272 | Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice |
| Q40469794 | Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. |
| Q33538555 | Vaccination against enteric pathogens: from science to vaccine trials |
| Q33876803 | Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 |
| Q40098097 | Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice |
| Q53581992 | Vaccine potential for inactivated shigellae. |
| Q39217803 | Vaccines against cholera, typhoid fever and shigellosis for developing countries |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
| Q36128243 | Vaccines based on the cell surface carbohydrates of pathogenic bacteria |
| Q91767150 | Vaccines for enteric diseases |
| Q41263122 | Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome. |
| Q79771810 | [Carbohydrates and vaccines: from purified polysaccharides to semi-synthetic glycoconjugate vaccines] |
Search more.